Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,853 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neutropaenia complications from Ocrelizumab and Rituximab treatment.
Pang V, Seery N, Wesselingh R, Yeh W, Zhong M, Tan T, Dwyer C, Nesbitt C, Rath L, Perera D, Bridge F, Skibina O, Bosco JJ, Jokubaitis V, Marriott M, Butkueven H, Van Der Walt A, Massey J, Sutton I, Monif M. Pang V, et al. Among authors: zhong m. Mult Scler Relat Disord. 2024 Jan;81:105147. doi: 10.1016/j.msard.2023.105147. Epub 2023 Nov 21. Mult Scler Relat Disord. 2024. PMID: 38043368 Free article.
MSCOVID19: Using social media to achieve rapid dissemination of health information.
Nesbitt C, Rath L, Yeh WZ, Zhong M, Wesselingh R, Monif M, Richards J, Minh VB, Jokubaitis VG, Skibina O, Butzkueven H, van der Walt A. Nesbitt C, et al. Among authors: zhong m. Mult Scler Relat Disord. 2020 Oct;45:102338. doi: 10.1016/j.msard.2020.102338. Epub 2020 Jun 24. Mult Scler Relat Disord. 2020. PMID: 32629402
Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic.
Rath L, Bui MV, Ellis J, Carey J, Baker J, Taylor L, Fernando H, Taylor N, Savage P, Richards J, Zhong M, Kalincik T, Skibina O, Wesselingh R, Nguyen AL, Monif M, Butzkueven H, van der Walt A. Rath L, et al. Among authors: zhong m. Mult Scler Relat Disord. 2021 Jan;47:102642. doi: 10.1016/j.msard.2020.102642. Epub 2020 Dec 1. Mult Scler Relat Disord. 2021. PMID: 33321356 Free PMC article.
Vaccinations in patients with multiple sclerosis: review and recommendations.
Nesbitt C, Rath L, Zhong M, Cheng AC, Butzkueven H, Wesselingh R, Skibina O, Monif M, Yeh W, Brotherton JM, Reddel S, Van Der Walt A. Nesbitt C, et al. Among authors: zhong m. Med J Aust. 2021 May;214(8):350-354.e1. doi: 10.5694/mja2.51012. Epub 2021 Apr 18. Med J Aust. 2021. PMID: 33866556 Review. No abstract available.
Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic Disorders.
Rath L, Campagna MP, Stankovich J, Ellis J, Jokubaitis V, McCarthy D, Nesbitt C, Yeh WZ, Zhong M, Wesselingh R, Monif M, Richards J, Minh VB, Skibina O, Butzkueven H, van der Walt A. Rath L, et al. Among authors: zhong m. Int J MS Care. 2021 May-Jun;23(3):114-118. doi: 10.7224/1537-2073.2020-075. Epub 2020 Dec 31. Int J MS Care. 2021. PMID: 34177383 Free PMC article.
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Zhong M, van der Walt A, Stankovich J, Kalincik T, Buzzard K, Skibina O, Boz C, Hodgkinson S, Slee M, Lechner-Scott J, Macdonell R, Prevost J, Kuhle J, Laureys G, Van Hijfte L, Alroughani R, Kermode AG, Butler E, Barnett M, Eichau S, van Pesch V, Grammond P, McCombe P, Karabudak R, Duquette P, Girard M, Taylor B, Yeh W, Monif M, Gresle M, Butzkueven H, Jokubaitis VG. Zhong M, et al. Mult Scler. 2022 May;28(6):958-969. doi: 10.1177/13524585211049986. Epub 2021 Oct 8. Mult Scler. 2022. PMID: 34623947
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Zhong M, van der Walt A, Monif M, Hodgkinson S, Eichau S, Kalincik T, Lechner-Scott J, Buzzard K, Skibina O, Van Pesch V, Butler E, Prevost J, Girard M, Oh J, Butzkueven H, Jokubaitis V. Zhong M, et al. Mult Scler. 2023 Jan;29(1):119-129. doi: 10.1177/13524585221111677. Epub 2022 Jul 27. Mult Scler. 2023. PMID: 35894247
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
Foong YC, Merlo D, Gresle M, Buzzard K, Zhong M, Yeh WZ, Jokubaitis V, Monif M, Skibina O, Ozakbas S, Patti F, Grammond P, Amato MP, Kalincik T, Horakova D, Kubala Havrdova E, Weinstock-Guttman B, Lechner Scott J, Boz C, Sa MJ, Butzkueven H, van der Walt A, Zhu C; MSBASE study group. Foong YC, et al. Among authors: zhong m. J Neurol Neurosurg Psychiatry. 2024 Jul 15;95(8):767-774. doi: 10.1136/jnnp-2023-332883. J Neurol Neurosurg Psychiatry. 2024. PMID: 38453478
3,853 results